drugset

drugset / Trial / NCT00328432

A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

NCT00328432 ↗

Phase 1 Completed 100 enrolled University of Kansas Pfizer · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.

Timeline

Start: 2003-06
Primary completion: —
Completion: 2005-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	400 mg	—

Indications